A literature study has shown that EZH2 is overexpressed in a variety of malignant tumors, especially solid tumors, and its expression is related to patients' clinical stage, tumor malignancy, tumor invasion and metastasis, chemotherapy resistance, and poor prognosis [9]. This evidence concerns the gene EZH2 and neoplasm.